Mandeville Therapeutics
Mandeville Therapeutics is developing disease-modifying therapies for chronic kidney disease (CKD) that target the underlying biological pathways driving renal deterioration, rather than merely managing symptoms. The company's approach aims to slow or halt disease progression, potentially changing the long-term trajectory for the millions of patients who currently face eventual progression to kidney failure.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Chronic kidney disease (CKD) is a progressive condition that affects millions of patients globally, yet current treatments primarily manage symptoms and complications rather than addressing the underlying disease mechanisms. The absence of disease-modifying therapies means most patients eventually progress to kidney failure, requiring dialysis or transplantation.
Solution
Mandeville Therapeutics is transforming the treatment of chronic kidney disease by developing therapies that target core disease pathways driving renal deterioration. The company's approach focuses on interventions that could slow or halt disease progression, offering an alternative to the current standard of care that largely manages symptoms. By addressing the biological drivers of CKD, Mandeville aims to change the trajectory of the disease for patients.
Target Audience
Primary customers are patients with chronic kidney disease and the nephrologists who treat them, as well as healthcare systems seeking therapies that reduce the burden of kidney failure.
Features
- Disease-modifying therapeutic approach targeting underlying CKD mechanisms
- Platform designed to address biological pathways not covered by existing treatments
- Development pipeline focused on changing the long-term progression of kidney disease